Cervix cancer screening in Croatia within the European cervical cancer prevention week [Probir raka vrata meternice u Hrvatskoj tijekom Europskog tjedna prevencije raka vrata maternice] by Škopljanac-Mačina, Lada et al.
Coll. Antropol. 34 (2010) 2: 613–617
Professional paper
Cervix Cancer Screening in Croatia within the
European Cervical Cancer Prevention Week
Lada [kopljanac-Ma~ina1, Vesna Mahovli}1, Ana Ovanin-Raki}1, Ana Bari{i}1, Sanda Rajhvajn1,
Danijela Juri~1, Damir Babi}2,5, Ante ]oru{i}3,5 and Slavko Ore{kovi}4,5
1 Department of Gynecologic Cytology, University Department of Gynecology and Obstetrics, Zagreb University Hospital Center,
Zagreb, Croatia
2 Department of Gynecologic and Perinatal Pathology, University Department of Clinical Pathology, Zagreb University Hospital
Center, Zagreb, Croatia
3 Department of Gynecologic Oncology, University Department of Gynecology and Obstetrics, Zagreb University Hospital Center,
Zagreb, Croatia
4 Department of Gynecology and Urogynecology, University Department of Gynecology and Obstetrics, Zagreb University Hospital
Center, Zagreb, Croatia
5 Zagreb University, School of Medicine, Zagreb, Croatia
A B S T R A C T
Croatia still has opportunistic screening and the organized national screening has been planned. The European Cer-
vical Cancer Prevention Week was held twice in Croatia, in January 2008 and 2009. Within the first one in 2008, infor-
mation campaign »For All Women« via mass media was held, and women were invited to the organized free gyneco-
logical examination and Papanicolaou test (Pap test) in the University Department of Gynecology and Obstetrics, Zagreb
University Hospital Center. Following invitation 481 women attended the testing; the median age was 55 years. There
were more women aged 50 (n=353), with the highest participation in the age group 55–59 years (n=94). Some women
came because of subjective symptoms (n=10), but the majority of them came only for testing (n=471). According to his-
tory of previous cytological testing, 400 women have had 1 negative findings, 71 women have had 1 positive findings, 9
women attended Pap test for the first time, and 1 woman does not know about previous testing. Cervical cytology was ab-
normal in 35 women (7.28%), the median age was 42 years with the highest proportion in the age group 30–34 years
(n=7); among all of them 21 women (60%) had no abnormal Pap test previously. The findings were: Atypical squamous
cells of undetermined significance – ASC-US (n=9), ASC cannot exclude high-grade squamous intraepithelial lesion –
ASC-H (n=1), cervical intraepithelial neoplasia – CIN 1 (n=13), CIN 2 (n=1), CIN 3 (n=6), carcinoma planocellulare
(n=2), atypical glandular cells – AGC-favor reactive endocervical cells (n=3). Among women aged 49 there were 20.47%
abnormal findings and among those aged 50, 2.55%. According to 1 positive Pap tests previously, among women aged
49 there were 30.71% while among those aged 50 there were 9.07%. Within the European Cervical Cancer Prevention
Week in 2009, employed women from one national company were invited by internal information to the same procedure.
A smaller group of younger asymptomatic women came for testing (n=53), median age 39 years. According to history of
previous cytological testing, 50 women have had 1 negative findings, 3 women have had 1 positive findings. In this
study, Pap test was positive in 3.77% (n=2). National screening programme should be focused on the participation of all
personally invited women, especially younger age groups and under-screened women. Well designed information cam-
paign should be implemented in national screening programme.
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Introduction
Cancer of the uterine cervix is an important cause of
morbidity and mortality among women worldwide and a
leading public problem. Because of the phases that pre-
cede the lesion in the natural progress of invasive cervical
613
Received for publication June 19, 2009
cancer, and because they can be easily discovered and
treated, the disease is well suited to screening programs.
The Papanicolaou (Pap) test is an established method for
examining the cells collected from the cervix to deter-
mine whether they show signs of pre-neoplastic dif-
ferentiation1. George Papanicolaou described a method
of cervical cancer diagnosis by cellular smear in 1928 and
later on he published two studies about the clinical use of
this test in 1941 and 19432–4. The American Cancer Soci-
ety endorsed the Papanicolaou smear (Pap test) in 19455.
Since then the method was introduced all over the world.
Centrally organized screening programmes started in
some developed countries in the 1960s and 1970s and
they were mostly local and regional programmes6. The
first national programmes started in Iceland 19697 and
Finland 19708. However, opportunistic screening is still
predominant in most European countries. Incidence and
mortality have decreased in the last decades in the north-
ern European countries with organized screening pro-
grammes, even more than 80%. In general, incidence and
mortality have declined in most of Europe. The cervical
cancer incidence varies in the different countries and
parts of the world, with age standardized (world) rate
(per 100 000) from >9.3 to <93.96,9.
In Croatia Pap test was introduced in 195310. Croatia
still has opportunistic cervix cancer screening and the
national screening programme has been planned10–14. Pi-
lot studies have been also performed in Croatia for more
than forty years15,16. The incidence rates of cervical can-
cer (per 100 000) in Croatia in 2006 were as follows:
crude rate 14.9; age-standardized (EU) rate 13.39; age-
-standardized (W) rate 10.59. In 2006 there were 343
new cases, and it was ranking eighth among cancer sites
in females. In the same year there were 458 new cases of
carcinoma in situ, and Ca in situ-invasive cancer ratio
was 57:4317.
The European Cervical Cancer Association (ECCA)
was established in 2003 to promote the implementation
of organized cervical cancer programmes equitably ac-
ross Europe as a whole. European Cervical Cancer Pre-
vention Week has been organized by the ECCA annually
in January, since 2007. It represents a number of actions
and public activities which promote awareness of cervical
cancer as a public health problem and the need of pre-
vention, and it is focused on the population as well as
politicians18.
The European Cervical Cancer Prevention Week was
held twice in Croatia, in 2008 and 2009. The ECCA
launched the Pearl of Wisdom Cervical Cancer Preven-
tion Awards on January 21, 2009, and among eight
awards one was presented to: »The people of Croatia for
their incredible efforts in hosting one of the most suc-
cessful Cervical Cancer Prevention Weeks of any Euro-
pean country in January of 2008. The range of actions
and the amount of awareness generated were phenome-
nal and the number of signatures collected for the STOP
Cervical Cancer Petition was one of the best in Eu-
rope«19.
The aim of the study was to evaluate the outcome of
information campaign and of public invitation to partici-
pation in organized screening.
Patients and Methods
Among other public activities during The European
Cervical Cancer Prevention Week in 2008, the informa-
tion campaign »For All Women« via mass media was
held. Women were invited to an organized free gyne-
cological examination and cytological testing in Univer-
sity Department of Gynecology and Obstetrics, Zagreb
University Hospital Center. After invitation, 481 women
attended the cervical cytological (Pap) testing. In 2009,
during another prevention week in Croatia, women em-
ployed in one national company were invited by internal
information to the same procedure, and 53 women came
for testing. In both studies women were invited to the ex-
amination during two weeks. The standard Pap test was
performed and interpreted following the Zagreb 2002
classification20.
Results
In 2008, there were 481 women aged 18–85, median
age 55 years (n=480, age data for 1 woman missing), the
highest participation was in the age group 55–59 years
(n=94). Some women came because of subjective symp-
toms (n=10), but the majority of them came only for test-
ing (n=471). According to history of previous cytological
testing, 400 women (83.16%) have had 1 negative find-
ing, 71 women (14.76%) have had 1 positive finding,
nine women (1.87%) came to testing for the first time,
and one woman (0.21%) does not know about previous
testing (Table 1).The entire group of women (n=480) can
be divided into two age groups, women aged 49 (n=127)
and women aged 50 (n=353). These two groups were
substantially different according to the percentage of
women with 1 positive cytological finding previously
(Table 2).
In our study abnormal cervical cytology was found in
35 (7.28%) women, aged 23–70, the median age 42 years,
with the highest proportion in the age group 30–34 years
(n=7). Among women aged 49 (n=127) there were 26
(20.47%) abnormal findings and among those aged 50
(n=353) there were 9 (2.55%) abnormal Pap tests (Table 3).
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TABLE 1
»FOR ALL WOMEN 2008« – PREVIOUS CERVICAL CYTOLOGICAL
FINDINGS (PAP TESTS)*
Pap tests N %
 1 negative 400 83.16
 1 positive 71 14.76
Never screened 9 1.87
Not sure 1 0.21
Total 481 100.00
*data source – interview
Among women with 1 negative cytological finding
previously (n=400) there were 21 abnormal smears
(5.25%). Among women with 1 positive cytological find-
ing previously (n=71) there were 14 abnormal smears
(19.72%). Among women who came for the first time to
cytological testing (n=9) and do not know about previous
testing (n=1) all the smears were negative (Table 4).
Further biopsy in our hospital was performed in 4 pa-
tients. The histological finding was cervical intraepithe-
lial neoplasia (CIN) 3 in 2 cases after abnormal cytologi-
cal findings, i.e. atypical squamous cells-cannot exclude
high-grade squamous intraepithelial lesion (ASC-H) and
CIN 3. The histological finding was negative in 2 cases
after cytological findings CIN 1 and carcinoma plano-
cellulare. The review of these two smears confirmed ab-
normal cytological findings in both cases.
In 2009, there were 53 women aged 25–54, the me-
dian age 39 years (n=52, age data for 1 woman missing),
and the highest participation was in the age group 35–39
years (n=17). All the women who came for testing had no
symptoms. According to history of previous cytological
testing, there were 50 women (94.34%) with 1 negative
finding, and 3 women (5.66%) with 1 positive finding. In
this study, cervical cytology was abnormal in 2 women
(3.77%). In one case the cytological finding was CIN 1 of
a woman aged 30, and in the other case it was atypical
glandular cells (AGC)-endocervical for a woman whose
age data is missing; both women had 1 negative cytolog-
ical findings previously. There were no biopsies per-
formed in our hospital afterwards. Among women with
1 negative cytological findings previously (n=50) there
were 2 abnormal smears (4.00%), and among women
with 1 positive cytological finding previously (n=3)
there were no abnormal smears.
Discussion
There is sufficient evidence that screening by conven-
tional cytology has reduced cervical cancer incidence and
mortality rates. Well organized screening programmes
are more cost-effective with a greater impact than oppor-
tunistic screening because they can achieve greater par-
ticipation and coverage of the target population, espe-
cially women at higher risk, with less harm due to
overscreening and overtreatment6.
Within the campaign »For All Women« in 2008, there
were almost 3 times more women aged 50 than those
aged 49. The percentage of women with previous 1 ab-
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TABLE 2
»FOR ALL WOMEN 2008« – PREVIOUS 1 POSITIVE PAP TEST
ACCORDING TO AGE
Age N
Previous 1 positive Pap tests
N %
49 127 39 30.71
50 353 32 9.07
Total 480 71 14.79
TABLE 3
»FOR ALL WOMEN 2008« – CYTOLOGICAL FINDINGS OF THE PAP TEST
Age group ASC-US ASC-H CIN 1 CIN 2 CIN 3 Carcinomaplanocellulare
AGC favor reactive
endocervical TOTAL
20–24 1 1
25–29 2 1 1 1 5
30–34 2 3 2 7
35–39 2 1 1 4
40–44 1 1 1 2 5
45–49 1 2 1 4
50–54 2 1 3
55–59 1 1
60–64 1 1 1 1 4
65–69 0
70–74 1 1
Total 9 1 13 1 6 2 3 35
ASC-US – atypical squamous cells of undetermined significance, ASC-H – ASC cannot exclude high-grade squamous intraepithelial le-
sion, CIN – cervical intraepithelial neoplasia, AGC – atypical glandular cells
TABLE 4
»FOR ALL WOMEN 2008« – POSITIVE PAP TESTS ACCORDING
TO THE PREVIOUS CYTOLOGY
Previous cytology N
Positive Pap test
N %
1 negative Pap test 400 21 5.25
1 positive Pap test 71 14 19.72
Came for the first time 9 0 0.00
Not sure 1 0 0.00
Total 481 35 7.28
normal smears was about 3 times higher in the women
aged 49 than in the older group, as well as in our study,
i.e. the percentage of abnormal Pap smears was even
about 8 times higher in the younger group (aged 49).
Within the Prevention Week in 2009, the invitation was
announced in a national company, and a smaller group of
younger women came for cervical testing. Comparing the
results of these two groups (in 2008 and 2009), the pro-
portion of women with 1 positive cytological findings
previously was substantially higher in the first study
(14.76% to 5.66%) as well as the percentage of abnormal
smears (7.28% to 3.77%), i.e. almost 2 times higher than
in the second study.
The relative participation of younger women in 2008
was low, and among them there were a higher percentage
of women with 1 positive findings previously, probably
associated with greater exposure to risk factors. Thus,
the young women should be planned as the target screen-
ing population, as well6,21. However, according to the out-
come of our study, the awareness of cervical cancer pre-
vention is better presented among older women.
In our study there were very few un-screened women.
Pap testing is often unevenly distributed among women,
with many of them not screened at all or under-screened
and other screened more frequently than recommended.
Over-testing is high in opportunistic screening6. The out-
come of campaign »For All Women« reflects the situation
in countries with opportunistic screening22–25, because
there were much more already screened women includ-
ing high proportion of those with 1 positive test previ-
ously. Within the future organized screening programme
in Croatia the mass media campaigns and public activi-
ties should be focused to reach younger age groups,
women at risk and under-screened women, with aim to
achieve the high coverage of target population. Personal
invitations with determined time and place of free test-
ing should be effective if the awareness of cancer risk and
cancer prevention is present among all women.
In Belgium, reported coverage of screening reached
only 59% but the number of the smears used was suffi-
cient to cover more than 100% of target population22. In
Croatia, the number of Pap tests taken yearly reached
433 671 in 2005, but it is clear that a large proportion of
target population remains un-screened and under-scre-
ened23. The population coverage by opportunistic screen-
ing was assessed in the Osijek-Baranja County in Croatia,
and it was 68% for the target population of women aged
25–64, that should be examined once in three years11.
The proportion of positive Pap tests in screening dif-
fers depending on the screened population6. In our study,
we found an overall rate of positive cytology being 7.28%
(in 2008) and 3.77% (in 2009), but the proportions of pos-
itive tests were different according to the age and to the
history of cervical cytology. Reported results of National
Breast and Cervical Cancer Early Detection Program
(NBCCEDP) showed that the prevalence of abnormal cy-
tological findings (squamous intraepithelial lesion – SIL
and carcinoma) was 3.8%26.
In Croatia, the age-standardised cervical cancer inci-
dence rates show a decreasing trend until the year 1991
but no further consistent decrease has been observed
afterwards23. The similar time trends are observed in
many developed countries, and this reflects the increas-
ing prevalence of human papillomavirus infection, mos-
tly in younger age groups6. Mass media campaigns combi-
ned with other strategies have been effective at increas-
ing either screening rates or early cancer detection27.
Conclusion
The future national screening programme should be
focused on the high participation of personally invited
women, especially younger age groups and under-scree-
ned women. The well designed information campaign
should be implemented in national screening programme.
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PROBIR RAKA VRATA MATERNICE U HRVATSKOJ TIJEKOM EUROPSKOG TJEDNA
PREVENCIJE RAKA VRATA MATERNICE
S A @ E T A K
Hrvatska jo{ uvijek ima oportunisti~ki probir raka vrata maternice, premda se unazad nekoliko godina planira orga-
nizirani nacionalni probir. Europski tjedan prevencije raka vrata maternice odr`ao se dva puta u Hrvatskoj, u sije~nju
2008. i 2009. godine. Tijekom prvoga od njih provela se promid`bena akcija »Za sve `ene« putemmasovnih medija, te su
`ene bile pozvane na organizirani besplatni ginekolo{ki pregled i Papa test u Klinici za `enske bolesti i porode Klini~kog
bolni~kog centra Zagreb. Nakon poziva do{la je 481 `ena srednje dobi 55 godina. Bilo je vi{e `ena dobi 50 (n=353), s
najve}im udjelom u dobnoj skupini 55–59 godina (n=94). Neke `ene su do{le zbog subjektivnih simptoma (n=10), a
ve}ina je do{la zbog preventivnog pregleda i Papanicolaou (Papa) testa (n=471). S obzirom na prethodnu citolo{ku
anamnezu, 400 `ena imalo je 1 negativan citolo{ki nalaz, 71 je imala 1 pozitivni citolo{ki nalaz, 9 ih je prvi put
pristupilo Papa testu, a 1 `ena ne zna. Citolo{ki nalaz bio je pozitivan u 35 `ena (7,28%), srednje dobi 42 godine, s
najve}im udjelom u dobnoj skupini 30–34 godine (n=7). Abnormalni citolo{ki nalazi bili su: atipi~ne plo~aste stanice
neodre|enoga zna~enja – engl. ASC-US (n=9), atipi~ne plo~aste stanice – ne mo`e se isklju~iti skvamozna intraepitelna
lezija visokog stupnja – engl. ASC-H (n=1), cervikalna intraepitelna neoplazija CIN 1 (n=13), CIN 2 (n=1), CIN 3
(n=6), Carcinoma planocellulare (n=2), atipi~ne glandularne stanice (engl. AGC) – endocervikalne, vjerojatno reak-
tivne promjene (n=3). Me|u `enama dobi 49 godina bilo je 20,47%, odnosno u dobi 50 godina 2,55% abnormalnih
citolo{kih nalaza. Me|utim kod `ena dobi 49 godina bilo je 30,71% s prethodno 1 pozitivnim citolo{kim nalazom, a u
skupini dobi 50 godina bilo ih je 9,07%. Tijekom Europskog tjedna prevencije raka vrata maternice 2009. godine poziv
je upu}en internom obavijesti `enama zaposlenima u jednoj nacionalnoj kompaniji. Do{la je manja grupa mla|ih `ena
(n=53), srednje dobi 39 godina. Sve su bile asimptomatske, a abnormalni Papa test na|en je u 3,77% (n=2). Nacionalni
program probira mora se usmjeriti na odaziv svih osobno pozvanih `ena, osobito mla|ih dobnih skupina i nedovoljno
skriniranih `ena. Promid`bena akcija mora se aktivno provoditi u sklopu nacionalnog programa probira.
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